Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 3/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.36 |
| ▸ | PPP1CC | P36873 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22486374 | 1.00 | PPM1B (0.36) | PPM1BPTPN1PPP1CCTP53CYP3A4 | |
| SCHEMBL21710114 | 1.00 | PPM1B (0.36) | PPM1BPTPN1PPP1CCTP53CYP3A4 | |
| SCHEMBL22239394 | 1.00 | PPM1B (0.36) | PPM1BPTPN1PPP1CCTP53CYP3A4 | |
| SCHEMBL14839282 | 1.00 | PPM1B (0.36) | PPM1BPTPN1PPP1CCTP53CYP3A4 | |
| SCHEMBL681569 | 1.00 | PPM1B (0.36) | PPM1BPTPN1PPP1CCTP53CYP3A4 | |
| SCHEMBL13592587 | 1.00 | PPM1B (0.36) | PPM1BPTPN1PPP1CCTP53CYP3A4 | |
| SCHEMBL16943369 | 0.95 | PPM1B (0.36) | PPM1BPTPN1PPP1CCTP53LMNA | |
| SCHEMBL23615814 | 0.95 | PPM1B (0.35) | PPM1BPTPN1PPP1CCTP53CYP3A4 | |
| SCHEMBL22058684 | 0.95 | PPM1B (0.35) | PPM1BPTPN1PPP1CCTP53CYP3A4 | |
| SCHEMBL14366763 | 0.95 | PPM1B (0.35) | PPM1BPTPN1PPP1CCTP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137564-A1 | NOVEL INCLUSION COMPOUND | NIPPON SODA CO., LTD. (JP) | 2017-05-18 | — | — | US | disclosed |
| US-20170137564-A1 | NOVEL INCLUSION COMPOUND | NIPPON SODA CO., LTD. (JP) | 2017-05-18 | — | — | US | disclosed |
| US-20160017088-A1 | NOVEL INCLUSION COMPOUND | NIPPON SODA CO., LTD. (JP) | 2016-01-21 | — | — | US | disclosed |
| US-20160017088-A1 | NOVEL INCLUSION COMPOUND | NIPPON SODA CO., LTD. (JP) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160017088-A1 | NOVEL INCLUSION COMPOUND | SEM1, C9, EIF4A1 | PPM1B 4765/4885PTPN1 4856/4885PPP1CC 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.